Topic:

Influenza

Latest Headlines

Latest Headlines

Takeda, Daiichi Sankyo ink flu vaccine distribution pacts with Japan's Kaketsuken

Pointing to a growing demand for seasonal flu vaccines in Japan, Takeda has signed on with the Chemo-Sero Therapeutic Research Institute (Kaketsuken) to sell one of the institute's seasonal shots while it continues distribution of another.

CSL CFO to lead flu vaccine business after 2016 launch

Australia's CSL will launch its new global flu vaccine business in early 2016, after it completes its $275 million acquisition of Novartis' flu vaccine unit.

Potency worries prompt GSK flu vaccine recall

To cap off one of the least effective seasons for flu vaccines in recent memory, vaccine producer GlaxoSmithKline announced the recall of all remaining doses of a quadrivalent, affecting roughly 1.7 million jabs.

UPDATED: Serum Institute and Bharat Biotech race to get swine flu vaccines back on the market

Swine flu is making a comeback in India, and with a vengeance. After destroying their existing stocks due to poor demand and short shelf life, Serum Institute and Bharat Biotech will be racing to get their swine flu vaccines back on the market.

VaxInnate reaps $53M for flu jab trials on BARDA contract extension

The U.S. Department of Health and Human Services apparently likes what it's seen from a 5-year contract with VaxInnate. Its Biomedical Advanced Research and Development Authority (BARDA) has extended the contract's base period with the flu vaccine maker, a move that allows for the use of $53 million.

Protein Sciences halts Connecticut expansion in response to governor's use of rival flu shot

Flu vaccine maker Protein Sciences may be abandoning its expansion plans in Connecticut, opting instead to build out its New York-based manufacturing site. But it's not for any of the reasons one might expect.

After rocky flu season, vaccinemakers may want to follow Novartis' lead

Heading into this year's flu season, vaccinemakers were hoping to follow up the top-line success they scored last year with quadrivalent rollouts. But with this year's vaccines registering a paltry 23% effectiveness rate this season thanks to a mutated strain, it might be time to make some changes.

Back from the scrap heap, BioCryst wins OK for IV flu drug

BioCryst Pharmaceuticals won its first-ever FDA approval for a new treatment and subsequently saw its shares slide as analysts yawned over its sales potential.

Sanofi adds another quadrivalent to its quiver with Fluzone Intradermal approval

Last year, Sanofi's fourth-quarter flu vaccine sales soared on the introduction of a quadrivalent contender, surging more than 94%. Now, looking to keep that growth coming, the company is adding another four-strain shot to the mix.

UPDATED: Novartis' Fluad off the hook in Italy following 19 deaths

After last week partially banning Novartis' Fluad, Italian officials now say tests on the flu vaccine show the product is safe.